5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of Tamoxifen in breast cancer cells

Biochemical Pharmacology

Volumn 86, Issue 1, 2013, Pages 175-189

  Segala, Gregory ^a,f   De Medina, Philippe ^a,b   Iuliano, Luigi ^d   Zerbinati, Chiara ^d   Paillasse, Michael R ^a,b   Noguer, Emmanuel ^a,b   Dalenc, Florence ^a,f   Payre, Bruno ^e   Jordan, V Craig ^c   Record, Michel ^a,f   Silvente Poirot, Sandrine ^a,f   Poirot, Marc ^a,f  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b Affichem   (France)

^c GEORGETOWN UNIVERSITY   (United States)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e Centre de Microscopie Electronique Appliquee A la Biologie   (France)

^f INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

AEBS; Breast cancer; ChEH; Cholesterol epoxide; Sulfation

Indexed keywords

5,6 EPOXY CHOLESTEROL; CHOLESTEROL DERIVATIVE; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; LOW DENSITY LIPOPROTEIN RECEPTOR; REACTIVE OXYGEN METABOLITE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TAMOXIFEN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 1 (2 (4 BENZYLPHENOXY)ETHYL)PYRROLIDIN HCL; 1-(2-(4-BENZYLPHENOXY)ETHYL)PYRROLIDIN-HCL; 5,6-EPOXYCHOLESTEROL; ANTINEOPLASTIC AGENT; CHOLESTEROL; CHOLESTEROL 5 ALPHA,6 ALPHA EPOXIDE HYDRASE; CHOLESTEROL 5,6 OXIDE; CHOLESTEROL-5 ALPHA,6 ALPHA-EPOXIDE HYDRASE; DRUG DERIVATIVE; EPOXIDE HYDROLASE; LIGAND; LIVER X RECEPTOR; ORPHAN NUCLEAR RECEPTOR; PYRROLIDINE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULFOTRANSFERASE; SULT2B1 PROTEIN, HUMAN;

ARTICLE; AUTOOXIDATION; BIOSYNTHESIS; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONCENTRATION (PARAMETERS); DRUG CYTOTOXICITY; EPOXIDATION; IC 50; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SULFATION; BINDING SITE; BREAST TUMOR; FEMALE; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CHOLESTEROL; EPOXIDE HYDROLASES; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; LIGANDS; ORPHAN NUCLEAR RECEPTORS; OXIDATION-REDUCTION; PYRROLIDINES; REACTIVE OXYGEN SPECIES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SULFOTRANSFERASES; TAMOXIFEN; TRIGLYCERIDES;

EID: 84884324369     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.02.031     Document Type: Article

References (71)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47.
3. Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 2007;7:46-53. (Pubitemid 46020846)
4. de Medina P, Favre G, Poirot M. Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. Curr Med Chem Anticancer Agents 2004;4:491-508. (Pubitemid 39406262)
5. Llaverias G, Danilo C, Mercier I, Daumer K, Capozza F, Williams TM, et al. Role of cholesterol in the development and progression of breast cancer. Am J Pathol 2011;178:402-12.
6. Danilo C, Frank PG. Cholesterol and breast cancer development. Curr Opin Pharmacol 2012;12:677-82.
7. Alikhani N, Ferguson RD, Novosyadlyy R, Gallagher EJ, Scheinman EJ, Yakar S, et al. Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene 2013;32:961-7.
8. Poirot M, Silvente-Poirot S, Weichselbaum RR. Cholesterol metabolism and resistance to tamoxifen. Curr Opin Pharmacol 2012;12:683-9.
9. Pitroda SP, Khodarev NN, Beckett MA, Kufe DW, Weichselbaum RR. MUC1- induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci USA 2009;106:5837-41.
10. de Medina P, Paillasse MR, Segala G, Khallouki F, Brillouet S, Dalenc F, et al. Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands. Chem Phys Lipids 2011;164:432-7.
11. Poirot M, De Medina P, Delarue F, Perie JJ, Klaebe A, Faye JC. Synthesis, binding and structure-affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS). Bioorg Med Chem 2000;8:2007-16. (Pubitemid 30612491)
12. Delarue F, Kedjouar B, Mesange F, Bayard F, Faye JC, Poirot M. Modifications of benzylphenoxy ethanamine antiestrogen molecules: influence affinity for antiestrogen binding site (AEBS) and cell cytotoxicity. Biochem Pharmacol 1999;57:657-61.
13. Fargin A, Bayard F, Faye JC, Traore M, Poirot M, Klaebe A, et al. Further evidence for a biological role of anti-estrogen-binding sites in mediating the growth inhibitory action of diphenylmethane derivatives. Chem Biol Interact 1988;66:101-9.
14. Brandes LJ. A diphenylmethane derivative selective for the anti-estrogen binding site may help define its biological role. Biochem Biophys Res Commun 1984;124:244-9. (Pubitemid 15207684)
15. de Medina P, Paillasse MR, Segala G, Poirot M, Silvente-Poirot S. Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands. Proc Natl Acad Sci USA 2010;107:13520-25.
16. Kedjouar B, de Medina P, Oulad-Abdelghani M, Payre B, Silvente-Poirot S, Favre G, et al. Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem 2004;279:34048-61. (Pubitemid 39063057)
17. Mesange F, Sebbar M, Capdevielle J, Guillemot JC, Ferrara P, Bayard F, et al. Identification of two tamoxifen target proteins by photolabeling with 4-(2- morpholinoethoxy)benzophenone. Bioconjug Chem 2002;13:766-72. (Pubitemid 34801119)
18. Mesange F, Sebbar M, Kedjouar B, Capdevielle J, Guillemot JC, Ferrara P, et al. Microsomal epoxide hydrolase of rat liver is a subunit of theanti-oestrogenbinding site. Biochem J 1998;334(Pt 1):107-12. (Pubitemid 28420978)
19. Poirot M, Chailleux C, Mesange F, Bayard F, Faye JC. Characterization of the membranous antiestrogen binding protein: II. Purification to homogeneity. J Recept Res 1994;14:37-46. (Pubitemid 24035479)
20. Chailleux C, Poirot M, Mesange F, Bayard F, Faye JC. Characterization of the membranous antiestrogen binding protein: I. Partial purification of the protein in its active state. J Recept Res 1994;14:23-35.
21. Poirot M, Chailleux C, Fargin A, Bayard F, Faye JC. A potent and selective photoaffinity probe for the anti-estrogen binding site of rat liver. J Biol Chem 1990;265:17039-43.
22. Deng T, Liu JC, Pritchard KI, Eisen A, Zacksenhaus E. Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine/tesmilifene. Clin Cancer Res 2009;15:119-30.
23. de Medina P, Payre B, Boubekeur N, Bertrand-Michel J, Terce F, Silvente-Poirot S, et al. Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism. Cell Death Differ 2009;16:1372-84.
24. Payre B, de Medina P, Boubekeur N, Mhamdi L, Bertrand-Michel J, Terce F, et al. Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Mol Cancer Ther 2008;7:3707-18.
25. Kedjouar B, Daunes S, Vilner BJ, Bowen WD, Klaebe A, Faye JC, et al. Structural similitudes between cytotoxic antiestrogen-binding site (AEBS) ligands and cytotoxic sigma receptor ligands. Evidence for a relationship between cytotoxicity and affinity for AEBS or sigma-2 receptor but not for sigma-1 receptor. Biochem Pharmacol 1999;58:1927-39.
26. Poirot M, Garnier M, Bayard F, Riviere I, Traore M, Wilson M, et al. The antiproliferative properties of 4-benzylphenoxy ethanamine derivatives are mediated by the anti-estrogen binding site (ABS), whereas the anti-estrogenic effects of trifluopromazine are not. Biochem Pharmacol 1990;40:425-9. (Pubitemid 20241104)
27. Brandes LJ, Gerrard JM, Bogdanovic RP, Lint DW, Reid RE, LaBella FS. Correlation of the antiproliferative action of diphenylmethane-derivative antiestrogen binding site ligands with antagonism of histamine binding but not of protein kinase C-mediated phosphorylation. Cancer Res 1988;48:3954-8.
28. Raghavan D, Brandes LJ, Klapp K, Snyder T, Styles E, Tsao-Wei D, et al. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. J Urol 2005;174:1808-13 [discussion 13]. (Pubitemid 41546946)
29. Khoo K, Brandes L, Reyno L, Arnold A, Dent S, Vandenberg T, et al. Phase II trial of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: a National Cancer Institute of Canada clinical trials group study. J Clin Oncol 1999;17:3431-7. (Pubitemid 29517911)
30. Brandes LJ, Bracken SP, Ramsey EW. N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine in combination with cyclophosphamide: an active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer. J Clin Oncol 1995;13:1398-403.
31. Brandes LJ, Simons KJ, Bracken SP, Warrington RC. Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,Ndiethyl- 2-[4-(phenylmethyl)phenoxy]ethanamine-HCl, in combination with various single antineoplastic agents. J Clin Oncol 1994;12:1281-90.
32. Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, et al. Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J Clin Oncol 2004;22:269-76. (Pubitemid 41095091)
33. Silvente-Poirot S, Poirot M. Cholesterol epoxide hydrolase and cancer. Curr Opin Pharmacol 2012;12:696-703.
34. de Medina P, Silvente-Poirot S, Tamoxifen Poirot M. AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy 2009;5:1066-7.
35. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012;8:445-544.
36. Schroepfer Jr. GJ. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol Rev 2000;80:361-554. (Pubitemid 30060568)
37. Cai H. NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ Res 2005;96:818-22. (Pubitemid 40604964)
38. Poirot M, Silvente-Poirot S. Cholesterol-5,6-epoxides. Chemistry, biochemistry, metabolic fate and cancer. Biochimie 2013;95:622-31.
39. Shah VP, Chegini HA, Vishneski SR, Weatherman RV, Blackmore PF, Dobrydneva Y. Tamoxifen promotes superoxide production in platelets by activation of PI3-kinase and NADPH oxidase pathways. Thromb Res 2012;129:36-42.
40. Chakraborty A, Bodipati N, Demonacos MK, Peddinti R, Ghosh K, Roy P. Long term induction by pterostilbene results in autophagy and cellular differentiation in MCF-7 cells via ROS dependent pathway. Mol Cell Endocrinol 2012;355:25-40.
41. Kallio A, Zheng A, Dahllund J, Heiskanen KM, Harkonen P. Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 2005;10:1395-410. (Pubitemid 43117684)
42. Lee YS, Kang YS, Lee SH, Kim JA. Role of NAD(P)H oxidase in the tamoxifeninduced generation of reactive oxygen species and apoptosis in HepG2 human hepatoblastoma cells. Cell Death Differ 2000;7:925-32.
43. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001;61:8492-7. (Pubitemid 33131130)
44. Jakobsson T, Treuter E, Gustafsson JA, Liver Steffensen KR. X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol Sci 2012;33:394-404.
45. Berrodin TJ, Shen Q, Quinet EM, Yudt MR, Freedman LP, Nagpal S. Identification of 5{alpha},6{alpha}-epoxycholesterol as a novel modulator of liver X receptor activity. Mol Pharmacol 2010;78:1046-58.
46. Lewis-Wambi JS, Kim H, Curpan R, Grigg R, Sarker MA, Jordan VC. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. Mol Pharmacol 2011;80:610-20.
47. de Medina P, Paillasse MR, Payre B, Silvente-Poirot S, Poirot M. Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases. J Med Chem 2009;52:7765-77.
48. Paillasse MR, de Medina P, Amouroux G, Mhamdi L, Poirot M, Silvente-Poirot S. Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion. J Lipid Res 2009;50:2203-11.
49. de Medina P, Casper R, Savouret JF, Poirot M. Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators. J Med Chem 2005;48:287-91. (Pubitemid 40105267)
50. de Medina P, Genovese S, Paillasse M, Mazaheri M, Subra-Caze S, Bystricky K, et al. Auraptene is an inhibitor of cholesterol esterification and a modulator of estrogen receptors. Mol Pharmacol 2010;78:827-36.
51. Song C, Hiipakka RA, Liao S. Auto-oxidized cholesterol sulfates are antagonistic ligands of liver X receptors: implications for the development and treatment of atherosclerosis. Steroids 2001;66:473-9. (Pubitemid 32140924)
52. Viennois E, Mouzat K, Dufour J, Morel L, Lobaccaro JM, Baron S. Selective liver X receptor modulators (SLiMs): what use in human health. Mol Cell Endocrinol 2012;351:129-41.
53. Fuda H, Javitt NB, Mitamura K, Ikegawa S, Strott CA. Oxysterols are substrates for cholesterol sulfotransferase. J Lipid Res 2007;48:1343-52. (Pubitemid 47312036)
54. Reed MJ, Purohit A, Woo LW, Newman SP, Potter BV. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev 2005;26:171-202.
55. Liao G, Yao Y, Liu J, Yu Z, Cheung S, Xie A, et al. Cholesterol accumulation is associated with lysosomal dysfunction and autophagic stress in Npc1 -/- mouse brain. Am J Pathol 2007;171:962-75. (Pubitemid 47440994)
56. Pacheco CD, Kunkel R, Lieberman AP. Autophagy in Niemann-Pick C disease is dependent upon Beclin-1 and responsive to lipid trafficking defects. Hum Mol Genet 2007;16:1495-503. (Pubitemid 47055121)
57. Porter FD, Scherrer DE, Lanier MH, Langmade SJ, Molugu V, Gale SE, et al. Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med 2010;2:56ra81.
58. Simons K, Gruenberg J. Jamming the endosomal system: lipid rafts and lysosomal storage diseases. Trends Cell Biol 2000;10:459-62.
59. Rao Malla R, Raghu H, Rao JS. Regulation of NADPH oxidase (Nox2) by lipid rafts in breast carcinoma cells. Int J Oncol 2010;37:1483-93.
60. He D, Meloche CA, Dumas NA, Frost AR, Falany CN. Different subcellular localization of sulphotransferase 2B1b in human placenta and prostate. Biochem J 2004;379:533-40. (Pubitemid 38703637)
61. Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology 2011;53:1023-34.
62. Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, et al. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl- CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem 2005;280:22212-21. (Pubitemid 40827878)
63. Ryan L, O'Callaghan YC, O'Brien NM. Comparison of the apoptotic processes induced by the oxysterols 7beta-hydroxycholesterol and cholesterol-5beta,6- beta-epoxide. Cell Biol Toxicol 2004;20:313-23. (Pubitemid 40558197)
64. Mandlekar S, Yu R, Tan TH, Kong AN. Activation of caspase-3 and c-Jun NH2- terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 2000;60:5995-6000.
65. Gundimeda U, Chen ZH, Gopalakrishna R. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem 1996;271:13504-14. (Pubitemid 26185395)
66. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990;82:1327-32. (Pubitemid 20238487)
67. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994;86:1534-9. (Pubitemid 24330218)
68. de Medina P, Payre BL, Bernad J, Bosser I, Pipy B, Silvente-Poirot S, et al. Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. J Pharmacol Exp Ther 2004;308:1165-73. (Pubitemid 38263994)
69. Suarez Y, Fernandez C, Gomez-Coronado D, Ferruelo AJ, Davalos A, Martinez- Botas J, et al. Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin. Cardiovasc Res 2004;64:346-55. (Pubitemid 39361697)
70. Patel R, Patel M, Tsai R, Lin V, Bookout AL, Zhang Y, et al. LXRbeta is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J Clin Invest 2011;121:431-41.
71. Babu JR, Sundravel S, Arumugam G, Renuka R, Deepa N, Sachdanandam P. Salubrious effect of vitamin C and vitamin E on tamoxifen-treated women in breast cancer with reference to plasma lipid and lipoprotein levels. Cancer Lett 2000;151:1-5. (Pubitemid 30155577)